Documente Academic
Documente Profesional
Documente Cultură
Researchers working with the Center for Gene and Cellular Therapies in the Treatment of Cancer
– OncoGen in Timişoara, in western Romania, have started testing a Covid-19 vaccine, the
center announced. The vaccine is currently meant for laboratory testing on human cells.
Cercetătorii care lucrează cu Centrul pentru terapie genică și celulară în tratamentul cancerului -
OncoGen din Timișoara, în vestul României, au început testarea unui vaccin impotriva Covid-19,
anunță centrul. În prezent, vaccinul este destinat testării în laborator pe celule umane.
OncoGen announced several weeks ago it was working on a vaccine, using a method that is
applied in the development of cancer immunotherapies, Virgil Păunescu, the director of
OncoGen, told HotNews.ro at the end of February.
OncoGen a anunțat încă de acum câteva săptămâni că lucrează la un vaccin, printr-o metodă
specifică dezvoltării imunoterapiilor în cancer, potrivit profesorului Virgil Păunescu, directorul
Institutului de cercetări medicale OncoGen, într-un interviu de la sfarsitul lunii februarie
pentru HotNews.ro.
Potrivit unei prezentări de pe site-ul OncoGen, institutul propune „o abordare inedită pentru
producerea de candidați pe bază de vaccin peptid pe bază de epitop pentru noul China
coronavirus (nCoV). [...] Abordarea pe care am folosit-o pentru proiectarea potențialilor
candidați pentru vaccinul peptidic are o strategie mai personalizată, denumită vaccinomică, care
permite selectarea proteinelor virale țintă cu rate de mutație scăzute și proiectarea peptidelor
adaptate la caracteristicile imune ale populații țintă, variabile în funcție de locația geografică și
de etnie. ”
Păunescu previously told Hotnews.ro that although Romania does not produce vaccines, the
development work was meant to “send a signal that we were there, working shoulder to shoulder
with those who have something to say.”
After developing a potential method to produce the vaccine, the OncoGen team published their
work on their website and sent it to other researchers in Europe and the United States, hoping to
help the countries that can produce vaccines.
“Our country does not currently have the resources to produce such a vaccine. But the
researchers from the OncoGen Center in Timișoara have sent the potential method of producing
the vaccine to their colleagues in countries in Europe and the United States, those who can take it
further, meaning to produce the vaccine,” Păunescu explained for Hotnews.ro.
„Țara noastră nu dispune în prezent de resursele necesare pentru a produce un astfel de vaccin.
Dar cercetătorii de la Centrul OncoGen din Timișoara au trimis potențialului procedeu de
producere a vaccinului colegilor lor din țări din Europa și Statele Unite, celor care îl pot duce
mai departe, în sensul de a produce vaccinul ”, a explicat Păunescu pentru Hotnews.ro .
The team of researchers in Timișoara says they already received feedback from some of their
colleagues and are working on improvements.
The team, made up of Florina Bojin, Oana Gavriliu, Michael-Bogdan Margineanu, and Virgil
Păunescu, published the article on February 8, on preprints.org, a platform dedicated to making
early versions of research outputs permanently available and citable. The article is titled “Design
of an Epitope-Based Synthetic Long Peptide Vaccine to Counteract the Novel China Coronavirus
(2019-nCoV).”
Echipa de cercetători formată din Florina Bojin, Oana Gavriliu, Michael-Bogdan Margineanu,
Virgil Păunescu publica, pe 8 februarie, articolul Design of an Epitope-Based Synthetic Long
Peptide Vaccine to Counteract the Novel China Coronavirus (2019-nCoV) într-o bază de date
care adună articole înainte ca acestea să fie acceptate spre publicare într-un jurnal de specialitate.
Un articol similar a fost publicat cu două săptămâni înainte pe site-ul propriu, susține OncoGen.
OncoGen says a similar article was published two weeks before on the institute’s website. They
later found out that on March 3, a group of Chinese researchers published an almost identical
article.
OncoGen said they were contacted by the embassy of China with the request to collaborate with
the Chinese researchers in implementing the novel technology. “We agreed and we have the
correspondence to prove this. But we did not agree with them taking over the results of our work
and then adding All Rights Reserved. So while the Romanian media sometimes wrote about it,
even ironically, the Chinese researchers were heavily inspired by it. Nonetheless, we will go
further with implementing our technology … even though the Romanian authorities saw
numerous references to this vaccine, nobody offered to lend a helping hand,” OncoGen
representatives said, quoted by Euractiv.ro.
The research OncoGen undertook about a potential Covid-19 vaccine derives from their research
on oncological immunotherapies, in an EU-funded project. Since 2016, OncoGen has been
involved together with Dresden University of Technology and Goethe University Frankfurt in
the research project- “Chimeric antigen receptor targeted oncoimmunotherapy with Natural
Killer cells,” Euractiv.ro reported.The project, amounting to RON 8.9 million (some EUR 2
million), is co-financed by the European Regional Development Fund under the Competitiveness
Operational Programme 2014-2020.
Cercetătorii români încep testele de laborator ale unui vaccin împotriva Covid-19